Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patients

Oral Oncol. 2022 Mar:126:105729. doi: 10.1016/j.oraloncology.2022.105729. Epub 2022 Feb 7.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Head and Neck Neoplasms* / drug therapy
  • Humans
  • Immune Checkpoint Inhibitors*
  • Lymphocytes
  • Neutrophils
  • Prognosis
  • Squamous Cell Carcinoma of Head and Neck / drug therapy

Substances

  • Immune Checkpoint Inhibitors